/indianstartupnews/media/agency_attachments/s1FnhAYONODoxNkoC8xA.png)
Follow Us/indianstartupnews/media/media_files/Fh8gZSAxK0KG2uUTqf3v.jpg)
Tata Capital Healthcare Fund II (TCHF II), a healthcare-focused private equity fund of Tata Capital Ltd., has invested approximately $20 million in Hyderabad-based Orbicular Pharmaceutical Technologies Private Limited.
The specialty pharmaceutical company will utilize the funding to accelerate the development of its product pipeline. The equity stake acquired by TCHF II remains undisclosed.
Specialty generics industry
The specialty generics industry, valued at over $60 billion, is expanding rapidly due to increasing demand for cost-effective alternatives to complex and high-cost branded medications. Orbicular has positioned itself as a significant player in this market with a robust pipeline of niche products.
These developments make the investment a strategic move for both Tata Capital Healthcare Fund and Orbicular, aiming to cater to the global demand for specialty generics.
Leadership comments
Visalakshi Chandramouli, Managing Partner of Tata Capital Healthcare Fund, expressed enthusiasm about the partnership, stating, “We are thrilled to partner with Orbicular which is at the forefront of R&D leadership in the field of complex generics. Under the able leadership of Dr. M.S. Mohan, Orbicular has developed a strong product pipeline for the regulated markets. This investment reinforces our fund’s core philosophy of identifying the big shifts in the industry and being a 'capital plus' partner to our companies.”
How will Orbicular benefit from the investment?
Dr M.S. Mohan, Managing Director of Orbicular, emphasized the transformative impact of the investment, noting, “Today is a transformative milestone in our journey of starting as a bootstrapped company to successfully being backed by Tata Capital Healthcare Fund. Having positioned Orbicular as a differentiated specialty pharmaceutical company in the complex generics space, the investment will further strengthen our global partnerships.”
Dr. Hiren Patel, Chief Executive Officer of Orbicular, added, “This new partnership with Tata Capital Healthcare Fund is a testament to our capabilities and will enable us to accelerate our R&D efforts, expand our portfolio, and strengthen our global partnerships.”